Vaccine inequality & low public acceptance inhibit vaccine uptake and limit coverage. Approximately 25m children under 1 year of age did not receive basic vaccines (highest since 2009). Global vaccine coverage dropped during COVID pandemic to 81%, and only 29% of population in developing countries were vaccinated against Covid. Our HIP-Vax platform can help solve these issues by shortening the time to the clinic and greatly reducing vaccine manufacturing costs. Our HIP-Vax platform helps make vaccines more affordable and allows for more equitable access.
Alfred Luitjens – Global Technical Sales Director – Batavia Biosciences
Alfred Luitjens is Global Technical Sales Director at Batavia Biosciences. He has a profound background in development and production of vaccines, with more than 30 years of experience. He worked for research & development at Solvay, DSM Biologics and Crucell. He had a management position at the Animal Science Group and was senior manager process architecture at GSK. At Batavia Biosciences, Alfred is responsible for writing all project proposals and key account management, advising organizations worldwide on vaccine development.